Mehmet F Okcu1, Kathleen D Aldrich1, Vincent E Horne2, Kevin Bielamowicz3, Rona Y Sonabend2, Michael E Scheurer1, Arnold C Paulino4, Anita Mahajan5, Murali Chintagumpala1, Austin L Brown6. 1. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. 2. Section of Diabetes and Endocrinology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. 3. Department of Pediatrics, The University of Arkansas for Medical Sciences, Little Rock, AR, USA. 4. Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Radiation Oncology, Mayo Clinic, Rochester, MN, USA. 6. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. Austin.Brown@bcm.edu.
Abstract
BACKGROUND: Endocrine deficiencies are common following Craniospinal irradiation (CSI) in children with brain tumors, but empirical data comparing outcomes following proton (PRT) and photon radiation therapy (XRT) are limited. METHODS: This retrospective chart review compared the incidence of hypothyroidism, Growth hormone deficiency (GHD), and Adrenal insufficiency (AI) in patients with medulloblastoma treated with XRT and PRT between 1997 and 2016. All patients received CSI and had routine endocrine screening labs to evaluate for thyroid dysfunction, GHD, and AI. We used proportional hazards regression to calculate hazard ratios (HR) and 95% confidence intervals (CI) comparing the development of hypothyroidism, AI, and GHD between radiation modalities, adjusting for age at diagnosis, sex, race/ethnicity, and CSI dose. RESULTS: We identified 118 patients with medulloblastoma who were followed for a median of 5.6 years from the end of radiotherapy. Thirty-five (31%) patients developed hypothyroidism, 71 (66%) GHD, and 20 (18%) AI. Compared to PRT, XRT was associated with a higher incidence of primary hypothyroidism (28% vs. 6%; HR = 4.61, 95% CI 1.2-17.7, p = 0.03). Central hypothyroidism, GHD, and AI incidence rates were similar between the groups. CONCLUSIONS: Primary hypothyroidism occurs less often after PRT CSI, compared to XRT CSI. This suggests that the thyroid and pituitary glands receive less radiation after spine and posterior fossa boost RT, respectively, using PRT.
BACKGROUND: Endocrine deficiencies are common following Craniospinal irradiation (CSI) in children with brain tumors, but empirical data comparing outcomes following proton (PRT) and photon radiation therapy (XRT) are limited. METHODS: This retrospective chart review compared the incidence of hypothyroidism, Growth hormone deficiency (GHD), and Adrenal insufficiency (AI) in patients with medulloblastoma treated with XRT and PRT between 1997 and 2016. All patients received CSI and had routine endocrine screening labs to evaluate for thyroid dysfunction, GHD, and AI. We used proportional hazards regression to calculate hazard ratios (HR) and 95% confidence intervals (CI) comparing the development of hypothyroidism, AI, and GHD between radiation modalities, adjusting for age at diagnosis, sex, race/ethnicity, and CSI dose. RESULTS: We identified 118 patients with medulloblastoma who were followed for a median of 5.6 years from the end of radiotherapy. Thirty-five (31%) patients developed hypothyroidism, 71 (66%) GHD, and 20 (18%) AI. Compared to PRT, XRT was associated with a higher incidence of primary hypothyroidism (28% vs. 6%; HR = 4.61, 95% CI 1.2-17.7, p = 0.03). Central hypothyroidism, GHD, and AI incidence rates were similar between the groups. CONCLUSIONS: Primary hypothyroidism occurs less often after PRT CSI, compared to XRT CSI. This suggests that the thyroid and pituitary glands receive less radiation after spine and posterior fossa boost RT, respectively, using PRT.
Authors: Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2014-01-31 Impact factor: 508.702
Authors: Sarah C Clement; Antoinette Y N Schouten-van Meeteren; Leontien C M Kremer; A S Paul van Trotsenburg; Huib N Caron; Hanneke M van Santen Journal: Pediatr Blood Cancer Date: 2014-08-17 Impact factor: 3.167
Authors: Sabine Mueller; Heather J Fullerton; Kayla Stratton; Wendy Leisenring; Rita E Weathers; Marilyn Stovall; Gregory T Armstrong; Robert E Goldsby; Roger J Packer; Charles A Sklar; Daniel C Bowers; Leslie L Robison; Kevin R Krull Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-14 Impact factor: 7.038
Authors: T Pasqualini; B Diez; H Domene; M E Escobar; L Gruñeiro; J J Heinrich; A Martinez; S Iorcansky; F Sackmann-Muriel; M Rivarola Journal: Cancer Date: 1987-02-15 Impact factor: 6.860
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Sujuan Huang; Kirsten K Ness; Wendy Leisenring; Melissa M Hudson; Sarah S Donaldson; Allison A King; Marilyn Stovall; Kevin R Krull; Leslie L Robison; Roger J Packer Journal: J Natl Cancer Inst Date: 2009-06-17 Impact factor: 11.816
Authors: Anita Mahajan; Helen Shih; Marta Penas-Prado; Keith Ligon; Kenneth Aldape; Leland S Hu; Ashlee R Loughan; Michael R Basso; Heather E Leeper; Brian V Nahed; Shannon L Stott; Susan Geyer; Caterina Giannini; Evanthia Galanis Journal: Cancers (Basel) Date: 2022-01-14 Impact factor: 6.575